Medicine, Hematology Oncology Division

Finished

Prot #JCAR017-FOL-001: A Phase 2, Open-Label, Single-Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects with Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (NHL) (Transcend FL)

Karmali, R.

ICON Clinical Research, LLC, Celgene Corporation

7/27/20 → 7/27/23

Project: Research project

Prot #ETCTN 10107/MC1721: Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and MK-3475 (Pembrolizumab) Compared to MK-3475 (Pembrolizumab) Alone for Mesothelin-Positive Malignant Pleural Mesothelioma

Mohindra, N. A.

Leidos Biomedical Research, Inc., Bayer HealthCare Pharmaceuticals, Inc.

7/21/20 → 8/30/21

Project: Research project

Prot #CX-839-012: A Phase 1b/2, Open label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with the CDK4/6 Inhibitor Palbociclib in Patients with Advanced or Metastatic Solid Tumors

Chae, Y. K.

Calithera Biosciences, Inc.

7/21/20 → 7/21/23

Project: Research project

Prot #RM-110: Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability and Efficacy of Rivoceranib or Trifluridine/Tipiracil as Monotherapies and Rivoceranib and Trifluridine/Tipiracil as Combination Therapy in Subjects with Metastatic Colorectal

Benson III, A. B.

Medpace Clinical Research LLC, Elevar Therapeutics, Inc.

7/16/20 → 7/16/23

Project: Research project

Prot #AMV564-301: A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Sosman, J. A.

Amphivena Therapeutics, Inc.

7/15/20 → 7/15/23

Project: Research project

Prot #EZH-1201: A Phase I, Open-Label Multi-Dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects With Moderate And Severe Hepatic Impairment With Advanced Malignancies

Mahalingam, D.

Pharmaceutical Research Associates, Inc., Epizyme, Inc.

7/8/20 → 7/8/23

Project: Research project

Prot #RMC-4630-02: A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 with Cobimetinib in Adult Participants with Relapsed/Refractory Solid Tumors and a Phase 1b Study of RMC-4630 with Osimertinib

Chae, Y. K.

PPD Investigator Services, LLC, Revolution Medicines, Inc.

7/7/20 → 7/7/23

Project: Research project

Par3 deficiency promotes fatty replacement in chronic pancreatitis

Shields, M.

American Pancreatic Association

7/1/20 → 5/31/21

Project: Research project

Prot #OMS-I103: The PISCES Study: A Multicenter Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressin

Chandra, S.

Precision Oncology, LLC, OncoSec Medical Incorporated

7/1/20 → 7/1/23

Project: Research project

A Novel ULK1 Pathway as a New Therapeutic Target in Melanoma

Nora Vaz Saleiro, D.

National Cancer Institute

7/1/20 → 6/30/23

Project: Research project

Targeting CysLTR1 in triple negative breast cancer

Zhang, B. & Cristofanilli, M.

U.S. Army Medical Research and Materiel Command

7/1/20 → 6/30/23

Project: Research project

Prot #CA209-76K: A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma.

Sosman, J. A.

Bristol-Myers Squibb Company

7/1/20 → 7/1/23

Project: Research project

Mechanisms of transformation and therapy resistance in myelodysplastic syndrome and acute myeloid leukemia

Crispino, J. D.

ASCO Cancer Foundation

7/1/20 → 6/30/21

Project: Research project

COVID19: Production of protein array for serum antibody screening

Platanias, L. C., Achenbach, C. J., Hultquist, J. F. & Satchell, K. J.

National Cancer Institute

7/1/20 → 1/31/22

Project: Research project

Engineering CpG Deoxynucleotide-Conjugated Gold Nanoparticles for Enhanced Anti-Lymphoma Effects

Gordon, L. I. & Lin, A. Y.

Lymphoma Research Foundation

7/1/20 → 6/30/22

Project: Research project

Prot #APL2-307: An Open-Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Efficacy of APL-2 in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Frankfurt, O.

Biorasi, LLC, Apellis Pharmaceuticals, Inc.

6/29/20 → 6/29/23

Project: Research project

Prot #IMGN632-0802: A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Altman, J. K.

Precision Oncology, LLC, ImmunoGen, Inc.

6/4/20 → 6/4/23

Project: Research project

Prot #20170528: A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Altman, J. K.

Amgen, Inc.

6/3/20 → 6/3/23

Project: Research project

Combinational DC vaccines and interventional Irreversible Electroporation for pancreatic ductal adenocarcinoma therapy.

Zhang, Z., Benson III, A. B., Ji, P., Salem, R. & Zhang, Z.

SIR Foundation

6/1/20 → 5/31/21

Project: Research project

Prot #PACT-0001: A Prospective Observational Cohort Study of Changes in the Neoepitope Specific T Cell Repertoire in Patients with Cancer

Sosman, J. A.

PACT Pharma, Inc.

6/1/20 → 6/1/23

Project: Research project

Prot #SMX 18-001: An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2−Breast Cancer with an ESR1 Mutat

Shah, A. N.

Linical Americas, Sermonix Pharmaceuticals, Inc.

5/28/20 → 5/28/23

Project: Research project

Prot #BNT411-01: Phase 1/2a, First-In-Human, Open-label, Dose-escalation Trial With Expansion Cohorts To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Efficacy Of BNT411 As A Monotherapy In Patients With Solid Tumors And In Combinat

Mahalingam, D.

ICON plc, BioNTech Small Molecules GmbH

5/27/20 → 5/27/23

Project: Research project

Prot #AV-951-18-121: A Phase 1b/2, Open-Label, Study of Tivozanib in Combination with Durvalumab in Subjects with Untreated Advanced Hepatocellular Carcinoma

Mahalingam, D.

Pharm-Olam International Ltd., AVEO Pharmaceuticals, Inc.

5/5/20 → 5/5/23

Project: Research project

Prot #RAIN-701: A Phase 2 Study to Evaluate the Clinical Activity of Tarloxotinib in Patients with Non-Small Cell Lung Cancer that Harbors Either an EGFR Exon 20 Insertion or a HER2-Activating Mutation and Other Advanced Solid Tumors with NRG1/ERBB Family

Patel, J. D.

NCGS, Inc., Rain Therapeutics Inc.

4/29/20 → 4/29/23

Project: Research project

Prot #NU FC19L02: TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, with or without Atezolizumab in Stage IV Non-squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

Patel, J. D.

National Comprehensive Cancer Network, Genentech, Inc.

4/21/20 → 4/21/23

Project: Research project

Medicine, Hematology Oncology Division

Grants

Search results